Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Bought by Algert Global LLC

Algert Global LLC raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 390.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 91,159 shares of the company's stock after purchasing an additional 72,556 shares during the period. Algert Global LLC owned 0.13% of Kiniksa Pharmaceuticals worth $2,278,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of KNSA. CWM LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $61,000 after purchasing an additional 1,998 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the first quarter valued at approximately $71,000. nVerses Capital LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $80,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the second quarter valued at approximately $100,000. Finally, Lynx1 Capital Management LP acquired a new position in shares of Kiniksa Pharmaceuticals in the second quarter valued at approximately $177,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on KNSA shares. Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a "buy" rating and a $40.00 price objective for the company. JPMorgan Chase & Co. upped their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Finally, Evercore ISI upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $36.60.

Insider Activity

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total transaction of $437,325.00. Following the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at $2,923,205.25. This represents a 13.01 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the transaction, the insider now owns 52,038 shares in the company, valued at $1,359,232.56. This trade represents a 53.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 95,192 shares of company stock worth $2,479,390. 54.57% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $22.04 on Wednesday. The firm has a fifty day moving average of $24.23 and a 200-day moving average of $22.91. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $15.52 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to analysts' expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals's revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.20) earnings per share. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.